Alzheimer's Disease (AD) and Type 2 Diabetes (T2D) share a common hallmark of insulin resistance. Besides Insulin Receptor (IR), two non-canonical RTKs, ALK and RYK, exhibit significant and consistent functional downregulation in post-mortem AD and T2D tissues. Incidentally, both have Grb2 as a common downstream adapter and NOX4 as a common ROS producing factor. Here we show that Grb2 and NOX4 play critical roles in reducing the severity of both the diseases. The study demonstrates that the abundance of Grb2 in degenerative conditions, in conjunction with NOX4, reverse cytoskeletal degradation by counterbalancing the network of small GTPases. PAX4, a transcription factor for both Grb2 and NOX4, emerges as the key link between the common pathways of AD and T2D. Both ALK and RYK downregulation elevate the PAX4 level by reducing its suppressor ARX via Wnt/β-Catenin signaling pathway. For the first time, this study brings together RTKs other than Insulin Receptor (IR), their common transcription factor PAX4 and both AD and T2D pathologies on a common regulatory platform.
Introduction
Epidemiological studies show that type 2 diabetes (T2D) increases the risk of Alzheimer's disease (AD) by at least 2-fold, although there are only a few mechanistic studies that provide a clear pathophysiological link (1) .
PET and MRI studies show marked impairment of glucose and energy metabolism in both T2D and AD (2) with amyloidogenesis being a salient feature in both. Reportedly, diabetic mice overexpressing islet amyloid polypeptide (IAPP) develop oligomers and fibrils with more severe diabetic trait akin to AD mice models overexpressing amyloid precursor protein (APP) (3) . Additionally, traits like insulin resistance, altered amyloid metabolism, synaptic dysfunction, activation of the inflammatory response pathways and impairment of autophagy have been shown as common pathological features in both the diseases (4) . With the understanding that several pathological signals are being shared by AD and T2D, AD has been suggested to be a neuroendocrine disorder resembling T2D (5) . Insulin receptor (IR), a receptor tyrosine kinase (RTK), further links both of them exhibiting resistance to insulin signaling and other metabolic disbalances. Our recent study lists the differential activities of several human RTKs in post-mortem brain tissues of AD patients and liver tissues of T2D patients and categorizes them into functional and regulational clusters (6) . Two RTKs, Anaplastic lymphoma kinase (ALK) and receptor-like tyrosine kinase (RYK), functionally behave in a similar fashion in both the disease situations (7) . Both ALK and RYK are involved in the regulation of Wnt/β-Catenin signaling (8) (9) (10) , which behaves aberrantly in both AD and T2D (11) . In a recent study both ALK and RYK were shown to have significantly decreased activities in AD and T2D conditions (7) .
Besides these pathways and signaling modalities, ROS mediated oxidative stress has been shown to be common in both the diseases (12) . A ROS producing NADPH oxidase, NOX4, is constitutively active with its regulatory protein tyrosine kinase substrate (Tsk4/5) with multiple SH3 domains (13) and interacts with Grb2 naturally (14, 15) . Reportedly, in AD post-mortem brain, in AD cell models as well as AD mouse model (APP/PS1 mouse) Grb2 transcript expression shows significant upregulation (16) . In AD brain, the NOX4 expression is significantly increased with substantial correlation between its activity and age-dependent increases of Aβ and cognitive dysfunction (17, 18) . In T2D, pancreatic β-cell dysfunction is promulgated by NOX4 overactivity and is sufficient to induce insulin resistance (19) . Growing number of evidence suggest that Nox4-derived ROS contributes to oxidative stress during the initial and chronic stages of T2D (20) .
In recent times the therapeutic potential of a cell-lineage specific transcription factor PAX4 is under scanner for T2D treatment (21) . In T2D, adult β-cell mass is prevented to re-enter the cell cycle through cyclin D1 and D2 or both. Forkhead transcription factor, FoxO1, interacts with PDX-1 to modulate β-cell proliferation (22) . Insulin inhibits FoxO1 through Akt-mediated phosphorylation and nuclear exclusion, which in turn increases the PDX1 expression and β-cell proliferation (23) . Here, PAX4 regulates the development of islets of Langerhans by increasing the β and δ-cells population (24) . Concomitantly, another transcription factor, Aristaless Related Homeobox (ARX), upregulates the α-cell population while reducing the β and δ-cells proliferation (25) . Furthermore, PAX4 and ARX are not only antagonistic functionally, they negatively regulate the transcriptions of their own genes (25, 26) . The transcription factor PAX4 has been shown to be involved in inducing regenerative capacity in insulin-positive islet cells in mice (21, 27) . PAX4 mutation have also been implicated in T2D (28) and its overexpression leads to β-cell proliferation and reduces apoptosis (29) . Only very recently PAX4 has been implicated in denervation in mice (30) and neurodegeneration, especially Parkinson's disease (31) . Reportedly, ARX mutation is associated with neurodegenerative and neurodevelopmental disorders through the impairment of the Wnt/β-Catenin signaling pathway (32) (33) (34) .
Hippocampal and select cortical neurons in AD manifest phenotypic changes indicative of neurons re-entering cell division cycle (35, 36) . Pathological signals trigger the Grb2/SOS/Ras cascade (37) that initiates cell cycle re-entry and proliferation but remains incomplete due to the lack of cell division machinery. Grb2 happens to be an important adapter of the insulin receptor and interestingly, insulin resistance is a noteworthy phenotype common to AD and T2D.
With this backdrop, the present study focuses on the regulation of both Grb2 and NOX4 by transcription factors like PAX4 and non-canonical RTKs in the context of AD and T2D. Consequences of pathological perturbations in both the diseases, starting from RTK signaling through their downstream effectors, have been tracked to link them with the cytoskeleton stability and the underpinning transcriptional regulation.
Specifically, the study attempt to interpret the effects of contrasting and extraneous signals, akin to AD and T2D, that utilize similar signaling gateways to achieve common outcome in two apparently diverse diseases.
Materials and Methods

AD and T2D human tissues
AD (NB820-59363) and Non-AD (NB820-59177) post-mortem whole brain lysates and Type 2 Diabetic (NB820-59232) and Non-Diabetic (NB820-59291) post-mortem whole liver lysates were purchased from Novus Biologicals. For statistical reasons we procured products from different patients with different lot numbers (for patients details see Table S1a and Table S1b ).
Ethics Statement
All animal experimentations using AD and T2D mouse models were conducted following the institutional guidelines for the use and care of animals and approved by the Institutional Animal and Ethics Committee of NBRC, Gurgaon (NBRC/IAEC/2012/71) and IICB, Kolkata (IICB/AEC/Meeting/2016/AUG), respectively.
AD and T2D mouse model
APP/PS1 or B6C3-Tg(/APPswe,PSEN1dE9/)85Dbo/J mice were obtained from the Jackson Laboratory (USA) and maintained. These transgenic mouse line for AD expresses human APPswe mutations (K670N and M671L) and exon 9-deleted human presenilin 1(PSEN1dE9) under the control of the mouse prion gene promoter. Animals were provided water and food /ad libitum/. The genotyping was carried out using PCR as described previously (38). The T2D model C57BL/6 mice 8-10 weeks of age were separated in two groups for normal chow and high-fat diet (HFD) containing 45% fat and 5.81 kcal/g diet energy content (# 960192; MP Biomedicals).
AD and T2D cell models, Cell culture, transfection, Plasmids, siRNAs and Antibodies
Clones of both AICD-GFP construct or 'AICD" and Grb2-DsRed construct or 'Grb2' were available in the lab (39-43). ALK (siRNA ID: s1269; no. 4392420), RYK (siRNA ID: s12390; no. 4390824) and PAX4 (Assay ID s10061, 4392420) siRNAs were purchased from ambion, life technologies TM . Aβ-peptide (A980), Sodium Palmitate (P9767) and Insulin (I9278-5ML) were purchased from Sigma-Aldrich. Amylin (ab142398) was purchased from Abcam. Antibodies were purchased from abcam and CST (see Table S2 for details).
Human neuroblastoma (SHSY-5Y) and liver carcinoma (HepG2) cell-lines were obtained from National Cell Science Centre, Pune, India and were cultured in respective media of DMEM-F12 (Gibco) and DMEM (Gibco) supplemented with 10% fetal bovine serum (Gibco) at 37°C in 5% CO2 atmosphere under humidified condition. Transfection of cells were done using Lipofectamine 2000 (Invitrogen) and as described [23] . For co-transfection, constructs were taken in equal proportions. Human neuroblastoma (SHSY-5Y) were transiently transfected with AICD and were externally treated with 0.5µM Aβ 1-42 (Sigma A980) for 3 hours after transfection and samples were collected after 48 hours of addition (44) . 0.75 mM aqueous Sodium Palmitate (Sigma P9767) along with 1% fatty acid free BSA (Sigma A8806-5G) was added to 24 hours serum starved media of HepG2 cells. Aqueous Amylin (Abcam ab142398) was added to the media at a final concentration of 0.5µM after 3 hours treatment of Palmitate. Samples were then collected after 16 hours with or without insulin (Sigma I9278-5ML) (100 nM) shock of 10 minutes.
Protein from mammalian cell
Phosphate buffer saline (PBS) washed pellet from cell lines were lysed on ice in lysis buffer (1M Tris-HCl, pH 7.5, 1N NaCl, 0.5 M EDTA, 1M NaF, 1M Na 3 VO 4 , 10% SDS, 20mM PMSF, 10% Triton X-100, 50% glycerol) for 30 min in presence of complete protease inhibitor (Roche Diagnostics) and centrifuged at 13,000 g for 15 min. Protein concentration was determined by Bradford protein estimation assay. Western blots and quantification were done as per described protocol (16) .
Fluorescence-activated cell sorting (FACS) and estimation of ROS activity
Palmitate/ Amylin treated HepG2 cells were harvested and stained with CM-H 2 DCFDA (5-(and-6)chloromethyl-2′,7′ dichlorodihydrofluoresceindiacetate, acetyl ester) according to manufacture's protocol.
The cells were then analysed for ROS activity by FACS (BD FACS Calibur platform, USA).
RNA isolation, c-DNA preparations and real time PCR
RNA was isolated from cells by TRIzol Reagent (Invitrogen,USA) extraction method following manufacturer's protocol which discussed in Majumder et al, 2017 (16) . Real time RT-PCR reaction was carried out using Syber green 2X Universal PCR Master Mix (Applied Biosystems, USA) in ABI Prism 7500 sequence detection system. The absolute quantification given by the software was in terms of CT values. The relative quantification of target genes was obtained by normalizing with internal control gene (GAPDH gene).
Primer sequences and PCR conditions are mentioned in Table S3 .
Chromatin Immuno Precipitation (ChIP)
We used High Sensitivity ChIP Kit (ab185913) to perform the ChIP assay and followed manufacturer's protocol. qRT-PCR analysis was done with the purified DNA using primers for GRB2 and NOX4 gene, more specifically around the PAX4 binding sequence. Primer details are given in Table S4 .
Statistical Analysis
Unpaired 't' test was carried out to compare the means of two experimental groups. The error bar represents standard error [(standard deviation/ √n); n= sample size]. To arrive at the statistically significant sample size for each experiment we did power analysis using the a priori model (45) as incorporated in the G*power 3.1 (46) software (16) .
Results
Expression of Grb2 and NOX4 increases in disease models and ALK/RYK doubleknock-down condition
Having known that Grb2 and NOX4 were common at the downstream of both AD and T2D, their 
PAX4 regulates the transcription of GRB2 and NOX4
While investigating for the molecular players behind GRB2 and NOX4 transcriptional upregulation, we used Transfac® MATCH1.0 (http://www.gene-regulation.com/pub/programs.html#match) online search tool to identify transcription factor binding sites upto 10Kb upstream of both GRB2 and NOX4 genes. In case of GRB2, 36 probable binding sites for 18 different transcription factors [Table S5 ] were found, whereas, for NOX4, 32 probable binding sites for 16 different transcription factors [Table S6 ] were found. Comparing the results for both GRB2 and NOX4, three (Nkx2-5, Foxd3 and PAX4) top hits were selected among the six common (Nkx2-5, Foxd3, PAX4, CHOP C/EBP, Oct1 and Evi-1) transcription factors. The transcript levels of these three transcription factors were measured for both AD and T2D cell models [ Fig. 2 A (i) and (ii)] and it was seen that whereas the mRNA levels of Nkx2-5 were downregulated those of PAX4 and FOXD3 were significantly upregulated in both the models. One could summarize from quantitative RT-PCR data that PAX4 showed maximum upregulation in both AD and T2D models where both GRB2 and NOX4 showed elevated expressions. PAX4 was thus selected as the major player behind altered expression of GRB2 and NOX4. PAX4 expression was measured by western blot and was found to be overexpressed in both AD and T2D cell models 
ARX correlates the ALK/RYK downregulation with PAX4 via β-Catenin signaling
In the course of exploring the mechanism behind PAX4 upregulation in the degenerative diseases, the role of ARX has emerged out in a significant way. The significant upregulation of ARX transcript level by 3. 
Expressions of cytoskeletal proteins change in conjunction with ALK/RYK deactivation
Discussion
This work unveils the commonality of two diverse diseases, AD and T2D. Over a decade, continuous efforts has been taken to establish a relationship between the two, but almost none of them focused on the signaling components and their possible convergence on a single transcription factor PAX4.
The precise common signaling mechanism for AD and T2D is still unclear, albeit the fact that both the diseases confer insulin resistance. Up until our recent work, Insulin Receptor (IR) was the only RTK known to be involved in the signaling of both diseases. Profiling the activities of other RTKs in the two diseases opened up a larger picture and the toxic effects of both Aβ and Amylin oligomers were predicted to have impacts on other receptor tyrosine kinases (7) . Amongst all the common RTKs, ALK and RYK were the two showing similar levels of deactivation in all working models of AD and T2D (7) . ALK, a member of insulin receptor superfamily, is commonly known for its involvement in many cancer types, especially in non-small-cell lung cancer (NSCLC) (50) . RYK is a co-receptor of non-canonical Wnt signaling (51) . Grb2 happens to be a common downstream adapter for both (52) . It was shown previously that Grb2 strengthened its interaction with NOX4 to rescue the cytoskeleton degradation in AD like situations (16) . We postulated that the two RTKs, ALK and RYK, might act like non-canonical receptors with the potential to become a significant link between AD and T2D via Grb2 and NOX4.
The downstream consequences at the molecular level, for both the signals, were significant compromise of cytoskeleton integrity. Interestingly, ALK and RYK double knockdown cell lines also resembled similar phenotypes [ Fig. 5 D and E] . Scanning the signaling pathways that could connect the common RTKs with downstream cytoskeleton degradation, we singled out Grb2 and NOX4, both of which had elevated levels in the disease scenarios [ Fig. 1 ]. Several reports on Grb2 strongly suggested its role in cellular survival in AD (41, 43) . Transcript levels of the cytoskeletal protein components were checked and were found to increase several folds with Grb2's overexpression in both AD (16) and T2D models [ Fig. 5 F] .
It was prudent therefore to try to understand the underpinning cellular mechanisms that help in the cytoskeletal restructuring, with possibly Grb2 playing a pivotal role. Activities of three small GTPases, RhoA, Rac1 and Cdc42, known to regulate cell morphology through rearrangement of cytoskeletal proteins (53-55) acting as molecular switches, were significantly altered and again renormalized with overexpression of Grb2. These alterations in the activities of small GTPases were sufficient to perturb the downstream signaling events and, ultimately, the cytoskeletal proteins degraded primarily through Cofilin mediated pathways. Cofilin is one of the downstream effectors of LIMK1 whose de-phosphorylation enables actin severing and depolymerizing activities (56) . These results convincingly implicated similar pathways for the rearrangement of the cytoskeleton network in AD and T2D. Grb2's intervention in both disease models significantly inactivates Cofilin by phosphorylation (16) [Fig. 6 B (a) (i), (b) (i)], a crucial regulator of actin Dynamics (57) . Similar to the case in AD, in reversing the signaling pathways involved in the degradation of cytoskeletal proteins, Grb2 was also involved in T2D as well. Abnormal NOX activation was reported in T2D (58) . NOX4 was found to interact with Grb2, activating Src (15) .
Adapter protein NOX4, from ROS production pathway, could also regulate Cofilin activity through Slingshot homolog-1 (SSH-1), the phosphatase of Cofilin. Both the disease models showed significant upregulation of NOX4, which was subsequently decreased with Grb2's overexpression [ Fig. 6 B(a) (ii) and (b) (ii)] (16).
These small checks and balances, at different levels along the signaling cascades, culminated in a larger scale perturbation in the cytoskeleton network and Grb2's role emerged out as that of reversal of these perturbations to some extent [ Fig. 5 F] (16) . Furthermore, while examining other effects on cytoskeleton integrity due to Grb2's overexpression, it was noted that NOX4 interacted with Grb2 in normal conditions (14, 15) which increased several folds under both AD (16) and T2D disease conditions [ Fig. 7 A] . As NOX4 was responsible for ROS generation, we also checked whether Grb2 overexpression could put a check on the ROS, which it could not. On the contrary, the ROS activity had increased in the presence of too much of Grb2 [ Fig. 7 B] .
This might be a hint towards the fact that even though the cells geared up the protective mechanisms, the defense was lost with the progression of the disease and beyond a threshold.
Eventually, the study unraveled the relation of ALK and RYK in controlling the cytoskeleton integrity through the overexpression of Grb2 and NOX4. Employing bioinformatics tools and quantitative real-time PCR, transcription factor, PAX4 was identified as a key regulator [ Fig. 2 A] . PAX4 is thought to be one of the crucial transcription factors that regulates the gene network governing β-cell mass expansion and survival under the pathophysiological conditions of T2D (59) . Recent studies have shown association of PAX4 mutations with T2D in Japanese and Afro-Americans population (28, 60) . However, PAX4 gene dysfunction would increase the susceptibility of apoptosis along with reducing cell proliferation leading to a gradual loss of β-cell and ultimately to diabetes (59) . Interestingly, the PI3K inhibitor, Wortmannin, showed potential to induce both insulin resistance and PAX4 expression (59, 61) . Naturally, PAX4 emerged as a survival gene because of its role in regulating both β-cell mass expansion and Grb2 expression. On the other hand, the mutual antagonism between PAX4 and ARX [ Fig. 4 A] connects the aberrant Wnt/β-Catening signaling with the upregulation of PAX4 by the reduction of ARX in both the diseases [ Fig. 4 B] . Nevertheless, this revelation assists to connect the dots between the deactivation of ALK and RYK with the downregulation of β-Catenin expression [ Fig. 4 C,D] level, followed by a decrease of ARX. Thus suggesting that the downregulation of ALK and RYK elevates the PAX4 level [ Fig. 2 B and 3 B] , which in turn upregulates Grb2 and NOX4 in both AD and T2D.
Additionally, NOX4 could induce mitochondrial dysfunction by inhibiting the mitochondrial chain complex 1 (62) . Alterations in the expression of genes coding for mitochondrial and cytoskeletal proteins contributed to the mitochondrial dysfunction observed in insulin-resistant conditions of both AD and T2D (63, 64) .
Interestingly, the majority of differentially expressed genes (DEGs) targeted by PAX4 were commonly enriched in both oxidative phosphorylation pathway (OXPHOS) and neurodegenerative diseases (31) .
Besides in T2D, this work established PAX4 as a promising candidate for a significant upregulation of GRB2 and NOX4, acting as the coveted 'missing link' between AD and T2D's common signaling pathways [ Fig. 2 B,C; Fig. 3 
